ANXA1 and irritable bowel syndrome: In biopsy-based analyses, AnxA1 immunostaining distinguished IBD from controls with an AUC of 0.82, sensitivity of 78%, and specificity of 74% (130 ).Meanwhile, single-cell and proteomic classifiers integrating AnxA1 improved performance to an AUC of ~0.90 in multi-gene panels (24).